Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: A retrospective analysis

Padhye, Bhavna; Dalla‐Pozza, Luciano; Little, David; Munns, Craig F

doi:10.1002/pbc.24563

Cited by 40 publications

(62 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The response depended on underlying etiology and general condition of the patient and also on the severity and type of joint involvement at the start of therapy. So far, lumbar spine BMD showed an increase after one year of treatment [23,71,72].…”

Section: Therapeutic Issuesmentioning

confidence: 99%

“…Based on the good results obtained in patients with osteogenesis imperfecta, drugs such as the bisphosphonates can clearly inhibit bone resorption when used in children either receiving anti-leukemic therapy or many years after the completion of therapy, even though the great experience is during ALL chemotherapy [23,[65][66][67][68][69][70][71][72].…”

Section: Therapeutic Issuesmentioning

confidence: 99%

“…Notwithstanding, the preventive use of ZA might potentially mitigate this side effect of current treatment regimens and is worthy in this sense, as this group of children are at risk of developing low bone mass during treatment; however, this bisphosphonate prophylaxis requires further evaluation, as this approach has been questioned by other authors [23,71,72].…”

Section: Therapeutic Issuesmentioning

confidence: 99%

“…Moreover, low bone mass might be the only manifestation of underlying childhood ALL [22]. Throughout chemotherapy, Avascular Necrosis (AVN) is a disabling complication in children and adolescents, especially secondary to steroids [23]. During therapy and many years after its withdrawal, low bone mass may be a consequence of therapy/disease; however, the degree of the decline of bone mass and its recovery are not well elucidated yet [10][11][12][13][14][15][16][17][18]21].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Are Survivors of Childhood Acute Lymphoblastic Leukemia at Increased Risk for Low Bone Mass?

Siviero-Miachon¹,

Lee²,

Guerra‐Júnior

et al. 2014

J Leuk

View full text Add to dashboard Cite

Acute lymphoblastic leukemia is the most prevalent cancer in children. As an increasing number of cancer survivors reaches adulthood, there may be consequences of the treatment, and there is an issue if low bone mass might be included as a significant late effect. Acute lymphoblastic leukemia patients may have their bone mass compromised during therapy and many years after its withdrawal, but the degree of bone mass decline or recovery are not well elucidated to date. Survivors of stem cell transplantation for leukemia have additional risk factors for bone loss and should be evaluated with caution. Our target is to make a warning about the difficulties in assessing and interpreting bone mass in children and adolescents, the limitations in this assessment in acute lymphoblastic leukemia young survivors (including survivors of stem cell transplantation), the possibility of misdiagnoses, the reasons (if there are any) of low bone mass in this particular group of cancer survivors, as well as consider the therapeutic issues available.

show abstract

Section: Therapeutic Issuesmentioning

confidence: 99%

Section: Therapeutic Issuesmentioning

confidence: 99%

Section: Therapeutic Issuesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Are Survivors of Childhood Acute Lymphoblastic Leukemia at Increased Risk for Low Bone Mass?

Siviero-Miachon¹,

Lee²,

Guerra‐Júnior

et al. 2014

J Leuk

View full text Add to dashboard Cite

show abstract

“…35 Bisphosphonates reduce osteoclast activity and prevent osteocyte and osteoblast apoptosis and thus might reduce the direct toxic effects of chemotherapy on bone cells. [36][37][38][39][40][41][42] Adrenocorticotropic hormone stimulates vascular endothelial growth factor, which enhances osteoblast activity and revascularization of necrotic bone. 43,44 The aforementioned pharmacological interventions might be of most significant impact when applied concomitant with antileukemic treatment associated with hypercoagulopathy and hyperlipidemia to prevent the occurrence of stage I ON and the progression to stage II ON.…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challenge

et al. 2017

View full text Add to dashboard Cite

Osteonecrosis (ON) represents one of the most common and debilitating sequelae of antileukemic treatment in children and adolescents with acute lymphoblastic leukemia (ALL). Systematic screening strategies can focus on early detection and intervention to prevent ON from progressing to stages associated with pain and functional impairment.These strategies hold promise for reducing ON-associated morbidity without the risk of impairing leukemia control. Herein, we critically reviewed clinical data on pharmacological, nonpharmacological/nonsurgical, and surgical (including cellular) treatment options for ON, which are covered in the literature and/or are conceivable based on the supposed underlying ON pathophysiology. Prevention of ON progression is of paramount importance, and attempts seem to be more effective in early (precollapse) disease status than in late-stage (collapse) ON. Based on the results of ongoing prospective magnetic resonance imaging screening studies, which will hopefully identify those patients with a high risk of ON progression and debilitating sequelae, prospective interventional studies are urgently needed. Although there is still a lack of high-quality studies, based on currently available data, core decompression surgery combined with cellular therapies (eg, employing mesenchymal stem cells) appears most promising for preventing joint infraction in children at high risk of developing late-stage ON.

show abstract

Zoledronate as effective treatment for minimal trauma fractures in a child with STAT3 deficiency and osteonecrosis of the hip

Boone

Alcántara-Montiel

Sánchez‐Sánchez

et al. 2016

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Signal transducer and activator of transcription 3 (STAT3) deficiency is a primary immunodeficiency characterized by eczema, complicated recurrent infections, elevated serum immunoglobulin E (IgE), osteopenia, and minimal trauma fractures. Zoledronic acid (ZA) is a long-acting bisphosphonate that has been successfully used in children with secondary osteoporosis and osteogenesis imperfecta. We describe the case of a 7-year-old male with STAT3 deficiency and minimal trauma fractures, who also developed osteonecrosis of the hip. He responded well to intravenous ZA every 6 months for 18 months. Three years later, he walks independently and unaided, and has not suffered any other fractures. Although more studies are needed, ZA might help reduce minimal trauma fractures in patients with STAT3 deficiency.

show abstract

Use of zoledronic acid for treatment of chemotherapy related osteonecrosis in children and adolescents: A retrospective analysis

Cited by 40 publications

References 40 publications

Are Survivors of Childhood Acute Lymphoblastic Leukemia at Increased Risk for Low Bone Mass?

Are Survivors of Childhood Acute Lymphoblastic Leukemia at Increased Risk for Low Bone Mass?

Osteonecrosis in children and adolescents with acute lymphoblastic leukemia: a therapeutic challenge

Zoledronate as effective treatment for minimal trauma fractures in a child with STAT3 deficiency and osteonecrosis of the hip

Contact Info

Product

Resources

About